Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
May 7, 2024
Assignee:
Takeda Vaccines, Inc.
Inventors:
Jill A. Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Asae Shintani, Holli Giebler, James Gifford, Mark Lyons, Sushma Kommareddy, Tatsuki Satou
Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
Type:
Grant
Filed:
September 13, 2022
Date of Patent:
April 23, 2024
Assignee:
Takeda Vaccines, Inc.
Inventors:
Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
Type:
Grant
Filed:
December 12, 2022
Date of Patent:
March 19, 2024
Assignee:
Takeda Vaccines, Inc.
Inventors:
Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
Abstract: The present invention relates to a method for removing host cell DNA from a sample comprising infectious viral particles and host cell DNA by anion exchange chromatography in the presence of at least one of a non-ionic surfactant, a sugar and a protein and to a method for purifying recombinant infectious viral particles from a host cell culture employing such an anion exchange chromatography step.
Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.
Type:
Grant
Filed:
June 15, 2021
Date of Patent:
November 28, 2023
Assignee:
Takeda Vaccines, Inc.
Inventors:
Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
Abstract: The invention relates to a single unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
Abstract: The present invention is directed to a method, i.e. an immunoassay, for determining the presence and/or the amount of anti-zika Anti-ZIKV #1 virus antibodies, i.e. zika virus-specific antibodies in a sample. Therefore, the present invention is directed to a microsphere complex comprising a microsphere coupled to a zika virus like particle, as well as to a kit comprising said microsphere complex and an amount of reporter antibody that binds to the zika virus like particle. The present invention further relates to a method for determining an antibody correlate of protection against zika virus infection for a zika virus vaccine. Moreover, the present invention is directed to a method for diagnosing the protection of a human or non-human subject against a zika virus infection.
Type:
Application
Filed:
May 19, 2021
Publication date:
October 12, 2023
Applicant:
Takeda Vaccines, Inc.
Inventors:
Erick PEREZ-GUZMAN, Eduardo NASCIMENTO, Hansi DEAN, Ralph BRAUN
Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
August 22, 2023
Assignee:
Takeda Vaccines, Inc.
Inventors:
Jill A Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Sushma Kommareddy
Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
Abstract: The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
July 18, 2023
Assignee:
Takeda Vaccines, Inc.
Inventors:
Charles Richardson, Thomas R. Foubert, Robert F. Bargatze, Paul Mendelman
Abstract: Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.
Type:
Grant
Filed:
October 5, 2020
Date of Patent:
July 18, 2023
Assignee:
TAKEDA VACCINES, INC.
Inventors:
Jill Ann Livengood, Linda Marie Strange, Steven Michael Erb
Abstract: The present disclosure relates to a method for determining the potency of an antigen sample such as a vaccine antigen sample. The present disclosure is also related to a method for monitoring the potency of a vaccine antigen during the production process including purifying, inactivating and formulating the vaccine antigen and to a method for producing a virus vaccine. Further, the present disclosure relates to vaccines obtainable by the methods disclosed. In certain embodiments of the present invention the antigen sample is a zika virus antigen sample.
Type:
Application
Filed:
March 19, 2021
Publication date:
June 29, 2023
Applicant:
Takeda Vaccines, Inc.
Inventors:
Jill LIVENGOOD, Michael JOHNSON, James GIFFORD, Tawnya NEAD, Mark LYONS, Jackie MARKS
Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
Type:
Application
Filed:
December 12, 2022
Publication date:
June 15, 2023
Applicants:
TAKEDA VACCINES INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY
Inventors:
Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
Abstract: The present invention relates to a method for removing host cell DNA from a sample comprising infectious viral particles and host cell DNA by anion exchange chromatography in the presence of at least one of a non-ionic surfactant, a sugar and a protein and to a method for purifying recombinant infectious viral particles from a host cell culture employing such an anion exchange chromatography step.
Type:
Application
Filed:
February 26, 2021
Publication date:
June 15, 2023
Applicant:
Takeda Vaccines, Inc.
Inventors:
Yock Ann LEE, Jia Vern LOH, Joseph David SANTANGELO
Abstract: The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of manufacture, formulation, testing, and uses thereof.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
May 16, 2023
Assignee:
Takeda Vaccines, Inc.
Inventors:
Jill A. Livengood, Holli Giebler, Whitney Baldwin, Hansi Dean, Claire Y. H. Kinney
Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
Type:
Application
Filed:
September 13, 2022
Publication date:
May 11, 2023
Applicant:
TAKEDA VACCINES, INC.
Inventors:
Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
Abstract: The present invention relates to methods for determining affinity, binding kinetics and/or concentration of an antibody or of an antibody mixture specific for a virus using virus-like particles (VLPs) and/or live viruses or inactivated viruses attached to biosensors. Further, the present invention relates to the VLPs and live or inactivated viruses attached to biosensors and methods for producing them.
Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
October 25, 2022
Assignee:
Takeda Vaccines, Inc.
Inventors:
Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford